Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.
Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.
复制标题
DOI：
10.1371/journal.pone.0098715
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Saeki T
中科院分区：
文献类型：
--
作者：
Ueda S;Kuji I;Shigekawa T;Takeuchi H;Sano H;Hirokawa E;Shimada H;Suzuki H;Oda M;Osaki A;Saeki T
测量组织血红蛋白浓度的光学成像技术最近已被接受为评估肿瘤血管和氧合的一种方法。我们研究了单药贝伐单抗的早期光学反应与治疗结果之间的相关性。7例晚期或转移性乳腺癌患者接受单药贝伐单抗治疗，随后每周添加紫杉醇。在基线和首次输注贝伐单抗后的第1、3、6、8和13天，对患者乳房进行光学成像，测量肿瘤总血红蛋白浓度（tHb）和氧饱和度（stO2）。为了评估早期代谢反应，在基线和两个疗程后进行了2-脱氧-2-(18F)-氟-d -葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）， 18F-氟米唑(FMISO)-PET/CT和磁共振成像。根据FDG-PET/CT测量的代谢反应，将7例患者分为有反应者（n = 4）和无反应者（n = 3）。在两个化疗周期结束时，与无反应者相比，反应者表现出显著的肿瘤缩小和较低的FMISO示踪剂积累。两组肿瘤均在治疗开始后第1天平均tHb明显衰减。无应答者的基线stO2水平低于邻近乳腺组织的stO2水平，并且在观察期间stO2水平稳定在较低水平。另一方面，应答者似乎维持高的stO2水平随时间波动。单药贝伐单抗治疗后肿瘤stO2水平低是无反应的特征。肿瘤stO2水平可能是贝伐单抗比紫杉醇提供的额外益处的预测因子。
Optical imaging techniques for measuring tissue hemoglobin concentration have been recently accepted as a way to assess tumor vascularity and oxygenation. We investigated the correlation between early optical response to single-agent bevacizumab and treatment outcome. Seven patients with advanced or metastatic breast cancer were treated with single-agent bevacizumab followed by addition of weekly paclitaxel. Optical imaging of patient's breasts was performed to measure tumor total hemoglobin concentration (tHb) and oxygen saturation (stO2) at baseline and on days 1, 3, 6, 8, and 13 after the first infusion of bevacizumab. To assess early metabolic response, 2-deoxy-2-(18F)-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT), 18F-fluoromisonidazole (FMISO)-PET/CT, and magnetic resonance imaging were performed at baseline and after two cycles of the regimen. Seven patients were grouped as responders (n = 4) and nonresponders (n = 3) on the basis of metabolic response measured by FDG-PET/CT. The responders showed remarkable tumor shrinkage and low accumulations of FMISO tracer relative to those of the nonresponders at the completion of two cycles of chemotherapy. Tumors of both groups showed remarkable attenuation of mean tHb as early as day 1 after therapy initiation. The nonresponders had lower baseline stO2 levels compared with adjacent breast tissue stO2 levels along with a pattern of steadily low stO2 levels during the observation window. On the other hand, the responders appeared to sustain high stO2 levels with temporal fluctuation. Low tumor stO2 level after single-agent bevacizumab treatment was characteristic of the nonresponders. Tumor stO2 level could be a predictor of an additional benefit of bevacizumab over that provided by paclitaxel.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
3.5
作者：
Cerussi, Albert;Shah, Natasha;Tromberg, Bruce J.
通讯作者：
Tromberg, Bruce J.
影响因子：
5.9
作者：
Mizukoshi, Waka;Kozawa, Eito;Kimura, Fumiko
通讯作者：
Kimura, Fumiko
影响因子：
33.6
作者：
Goel S;Duda DG;Xu L;Munn LL;Boucher Y;Fukumura D;Jain RK
通讯作者：
Jain RK
DOI：
10.1038/nrclinonc.2009.63
发表时间：
2009-06
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
通讯作者：
--